A5072066533- Inflammatory Bowel Disease
- Eosinophilic Esophagitis
- Nutrition and Health in Aging
- Microscopic Colitis
- Pregnancy and Medication Impact
- Dysphagia Assessment and Management
- IL-33, ST2, and ILC Pathways
- Helicobacter pylori-related gastroenterology studies
- Gut microbiota and health
- Gastric Cancer Management and Outcomes
- Autoimmune and Inflammatory Disorders
- Chronic Disease Management Strategies
University of Glasgow
2022-2024
Glasgow Royal Infirmary
2023-2024
Abstract Background and Aims Micronutrient deficiencies are common in patients with inflammatory bowel disease (IBD), but whether they relate to outcomes remains unknown. This study assessed the micronutrient status of adults IBD on treatment biologic therapies explored predictive relationships outcomes. Methods Seventeen micronutrients were measured blood 216 therapy. Of these, 127 (58%) had Crohn’s (CD), majority (70%) received infliximab. Patients followed for 12 months onset adverse...
Enteral nutrition (EN) involves replacing all or part of a person's habitual diet with nutritional formula. The impact varying doses EN on the gut microbiome remains understudied.
The immunological effects of treatment with exclusive enteral nutrition (EEN) in Crohn's disease (CD) remain unknown. We characterized the plasma levels inflammation-related proteins (IRPs) children CD and ulcerative colitis (UC) compared noninflammatory controls (non-IBD) explored effect EEN CD.
Abstract Background and Aims Treatment adherence is key to the efficacy of exclusive enteral nutrition [100% EN] in active Crohn’s disease [CD], but there are no biomarkers objectively estimate this. We explored faecal parameters as compliance with 100% EN, subsequently developed validated Glasgow Exclusive Enteral Nutrition Index Compliance [GENIE]. Methods Healthy adults replaced all or part [85% 50% 20% their diet a formula for 7 days. Faecal pH, water content, short chain fatty acids,...
Abstract Background Biologics such as adalimumab (ADA) are used to induce clinical remission (CR) in individuals with active Crohn’s disease (CD) but around 50% of patients actually achieve remission. Exclusive enteral nutrition is also an effective induction treatment, tolerability limits its use, especially adults. This study aimed assess the efficacy and partial (PEN) combination ADA compared monotherapy. Methods In this multi-centre (n=8) RCT (NCT04859088), adults CD (Crohn’s Disease...
Exclusive enteral nutrition (EEN) and partial (PEN) remain the only established dietary therapies in Crohn's disease (CD) management. We conducted a questionnaire survey to evaluate perceptions of adults with CD toward emerging food-based therapies.
Abstract Background Biologics, such as anti-TNFα agents, are commonly used in the management of Crohn’s disease (CD). A significant proportion patients do not respond to treatment, necessitating exploration pre-treatment predictors treatment response. Methods Anti-TNFα-naïve adults with active CD (Crohn’s Disease Activity Index; CDAI≥150) participating an RCT (NCT04859088) were randomised receive adalimumab monotherapy or combination therapy 50% partial enteral nutrition (PEN). Treatment...
Abstract Background Exclusive enteral nutrition (EEN) and partial (PEN), replacing at least 50% of the energy intake with formula, remain only evidence-based dietary therapies in management Crohn’s disease (CD). Nonetheless, emerging solid food-based are being researched to offer equally effective, but more palatable alternatives. We assessed perceptions adults CD towards EEN, PEN, novel within a cross-sectional questionnaire survey. Methods The 26-question anonymous survey pre-paid return...
Abstract Background Treatment adherence is key to the efficacy of exclusive enteral nutrition (100% EN) in active Crohn’s disease (CD), but there are currently no biomarkers objectively support this. We explored faecal parameters as putative compliance with 100% EN, and subsequently developed validated Glasgow Exclusive Nutrition Index compliancE (GENIE). Methods Healthy adults replaced all or part (85% 50% EN 25% their habitual diet a polymeric formula (Modulen IBD, Nestle©) for 7 days....